Related Experiment Videos
Therapy of lymphoma directed at idiotypes
1Department of Medicine, Stanford University Medical Center, CA 94305-5306.
Journal of the National Cancer Institute. Monographs
|January 1, 1990
Summary
Anti-idiotype monoclonal antibodies show promise for B-cell cancer, demonstrating antitumor effects with low toxicity. These antibodies can be reused and combined with other therapies for improved patient outcomes.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Anti-idiotype monoclonal antibodies are available for a significant portion of B-cell cancer patients.
- Cross-reactivity of patient-derived antibodies with shared idiotype determinants on tumor cells enables this approach.
Purpose of the Study:
- To evaluate the efficacy and safety of anti-idiotype monoclonal antibodies in B-cell cancer patients.
- To explore the potential for repetitive use and combination therapies.
Main Methods:
- Clinical trials involving patients with B-cell malignancies who have exhausted conventional treatments.
- Administration of anti-idiotype monoclonal antibodies targeting shared tumor idiotype antigens.
Main Results:
- Demonstrated reproducible antitumor effects in patients refractory to standard therapies.
- Treatment exhibited minimal toxicity and rare induction of immune responses.
- The antibodies were suitable for repetitive administration.
Conclusions:
- Anti-idiotype monoclonal antibodies represent a viable therapeutic option for B-cell cancers.
- Their favorable safety profile allows for repeated use and combination with other treatments.
- Future research directions include combination strategies and active immunotherapy induction.